Related Experiment Video
Updated: Dec 24, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Advances in targeted therapy for malignant lymphoma
Li Wang1,2, Wei Qin1, Yu-Jia Huo1
1State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, China.
Abstract:
The incidence of lymphoma has gradually increased over previous decades, and it ranks among the ten most prevalent cancers worldwide. With the development of targeted therapeutic strategies, though a subset of lymphoma patients has become curable, the treatment of refractory and relapsed diseases remains challenging. Many efforts have been made to explore new targets and to develop corresponding therapies. In addition to novel antibodies targeting surface antigens and small molecular inhibitors targeting oncogenic signaling pathways and tumor suppressors, immune checkpoint inhibitors and chimeric antigen receptor T-cells have been rapidly developed to target the tumor microenvironment. Although these targeted agents have shown great success in treating lymphoma patients, adverse events should be noted. The selection of the most suitable candidates, optimal dosage, and effective combinations warrant further investigation. In this review, we systematically outlined the advances in targeted therapy for malignant lymphoma, providing a clinical rationale for mechanism-based lymphoma treatment in the era of precision medicine.
Insights
Targeted therapies offer new hope for lymphoma patients, but challenges remain in treating relapsed or refractory disease. This review details advances in precision medicine for lymphoma treatment.
Area of Science:
- Oncology
- Hematology
- Cancer Therapeutics
Background:
- Lymphoma incidence is rising globally, ranking among the top ten cancers.
- While targeted therapies improve outcomes for some, refractory and relapsed lymphoma remain difficult to treat.
- Significant research is ongoing to identify new therapeutic targets and strategies.
Purpose of the Study:
- To systematically review advances in targeted therapy for malignant lymphoma.
- To provide a clinical rationale for mechanism-based lymphoma treatment in the era of precision medicine.
Main Methods:
- Comprehensive literature review of targeted therapeutic strategies for lymphoma.
- Analysis of novel antibodies, small molecular inhibitors, immune checkpoint inhibitors, and CAR T-cell therapies.
- Evaluation of clinical data and research on targeted agents and their impact on the tumor microenvironment.
Main Results:
- Targeted agents including novel antibodies and small molecule inhibitors show promise.
- Immune checkpoint inhibitors and CAR T-cells represent rapidly developing strategies targeting the tumor microenvironment.
- Despite successes, adverse events require careful consideration, and optimal treatment selection, dosage, and combinations need further study.
Conclusions:
- Precision medicine offers a framework for mechanism-based lymphoma treatment.
- Continued research is crucial to optimize targeted therapies and overcome challenges in refractory and relapsed lymphoma.
- Further investigation into candidate selection, dosage, and combination therapies is warranted for improved patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers